MX2022010780A - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. - Google Patents

Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.

Info

Publication number
MX2022010780A
MX2022010780A MX2022010780A MX2022010780A MX2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A
Authority
MX
Mexico
Prior art keywords
tapentadol
dosage form
prolonged release
phosphoric acid
acid salt
Prior art date
Application number
MX2022010780A
Other languages
English (en)
Spanish (es)
Inventor
Ulrike Bertram
Ulrich Reinhold
Christian Grosse
Carmen Hartmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74701506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022010780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20160419.6A external-priority patent/EP3875077B1/de
Priority claimed from EP20160420.4A external-priority patent/EP3875079A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2022010780A publication Critical patent/MX2022010780A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022010780A 2020-03-02 2021-03-01 Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. MX2022010780A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160419.6A EP3875077B1 (de) 2020-03-02 2020-03-02 Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
EP20160420.4A EP3875079A1 (de) 2020-03-02 2020-03-02 Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
PCT/EP2021/055025 WO2021175773A1 (en) 2020-03-02 2021-03-01 Dosage form providing prolonged release of tapentadol phosphoric acid salt

Publications (1)

Publication Number Publication Date
MX2022010780A true MX2022010780A (es) 2022-09-26

Family

ID=74701506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010780A MX2022010780A (es) 2020-03-02 2021-03-01 Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.

Country Status (7)

Country Link
EP (1) EP4003318A1 (de)
BR (1) BR112022017700A2 (de)
CO (1) CO2022012567A2 (de)
DE (1) DE202021003994U1 (de)
MX (1) MX2022010780A (de)
PE (1) PE20230105A1 (de)
WO (1) WO2021175773A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
WO2006002886A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CA2667925A1 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
PE20190391A1 (es) 2008-10-30 2019-03-13 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
WO2012010316A1 (en) 2010-07-23 2012-01-26 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP3027214A1 (de) 2013-08-02 2016-06-08 ratiopharm GmbH Zusammensetzung mit tapentadol in gelöster form
EP2942054A1 (de) 2014-05-09 2015-11-11 G.L. Pharma GmbH Pharmazeutische Formulierung mit langsamer Wirkstoffabgabe
DK3445742T3 (da) 2016-04-19 2020-02-24 Ratiopharm Gmbh Krystallin tapentadolphosphat
WO2018219897A1 (en) 2017-05-29 2018-12-06 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Also Published As

Publication number Publication date
EP4003318A1 (de) 2022-06-01
DE202021003994U1 (de) 2022-04-12
WO2021175773A1 (en) 2021-09-10
PE20230105A1 (es) 2023-01-25
BR112022017700A2 (pt) 2023-01-17
CO2022012567A2 (es) 2022-09-09

Similar Documents

Publication Publication Date Title
IL273194B2 (en) Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
AU2017265011B2 (en) Methods of administering high concentrations of nitric oxide
MX2020006650A (es) Esketamina para el tratamiento de la depresión.
US20070110676A1 (en) Compositions useful for prevention and treatment of common cold and influenza-like symptoms
MX362452B (es) Tratamiento de degeneracion macular relacionada con la edad (amd) usando virus asociados con adeno (aav) sflt-1.
EP4378484A3 (de) Formulierung für anti-alpha4beta7-antikörper
MX2022010780A (es) Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
MX2008010155A (es) Composiciones virucidales que contienen metal y sus usos.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX2016015417A (es) Multiparticulas protegidas contra vertido de dosis etanolico.
MX360389B (es) Formulacion farmaceutica o nutraceutica resistente a fluidos gastricos que comprende una o mas sales de acido alginico.
MX2019013372A (es) Composiciones de neisseria meningitidis y sus metodos.
BR112015026053A2 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
SI2646011T1 (en) Procedures for reducing disturbance or compulsive overeating
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
IL303225A (en) Reducing viral infections
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
KR20200052310A (ko) 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
Esteban-Sanchez Lidocaine/prilocaine overdose